Clarity wanted: When can new drug price negotiations be challenged in court?
The inevitable lawsuit over the incoming rules around how the CMS plans to negotiate some of the most expensive drug prices has the Congressional Research Service already calling on Congress to be more clear about the types of legal challenges it intends to prohibit under the new law.
Gilead recently said that select provisions of the Inflation Reduction Act “may become subject to legal challenges” even as the CRS points to speculative areas that may be challenged and certain areas that may not be subject to judicial review.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.